Publications
Detailed Information
The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Bomi | - |
dc.contributor.author | Myung, Jae Kyung | - |
dc.contributor.author | Seo, Ja Hee | - |
dc.contributor.author | Park, Chul-Kee | - |
dc.contributor.author | Kim, Dong Gyu | - |
dc.contributor.author | Park, Sung-Hye | - |
dc.contributor.author | Jung, Hee-Won | - |
dc.contributor.author | Paek, Sun Ha | - |
dc.date.accessioned | 2012-05-31T05:16:13Z | - |
dc.date.available | 2012-05-31T05:16:13Z | - |
dc.date.issued | 2010-07-15 | - |
dc.identifier.citation | JOURNAL OF THE NEUROLOGICAL SCIENCES; Vol.294; 112-118 | ko_KR |
dc.identifier.issn | 0022-510X | - |
dc.identifier.uri | https://hdl.handle.net/10371/76672 | - |
dc.description.abstract | Glioblastoma (GBM) is a malignant CNS neoplasm. The prognosis of GBM may be influenced by the molecules of p53/MDM2/p14ARF. RB/p16INK4a, and the EGFR/PTEN/protein kinase B (PKB)/phosphoinositide 3-kinase (PI3K) pathways. We studied the expression status of specific molecular markers in GBMs by immunohistochemistry (INC) and FISH in correlation with the clinical outcomes. The positivity of EGFR FISH and those of EGFR IHC by pharmDx and Zymed antibodies were 64.9%, 73.5%, and 43.4%, respectively. EGFR pharmDx antibody was more sensitive but less specific than EGFR Zymed antibody. p53 overexpression. MDM2 expression, p16 loss, PTEN loss, PKB and PI3K expression were found in 48.2%, 26.5%, 56.6%, 21.4%, 15.7% and 6.0%, respectively. EGFR IHC and FISH significantly, although not completely, correlated and EGFR and p53 immunoexpression also showed positive correlation. On multivariate survival studies, old age (>= 40 yrs) and bilaterality were independent unfavorable prognosis factors (p<0.05). Stratified by age, resectability and tumor size <5 cm were favorable survival factors in young (40= 40 yrs), respectively. Furthermore, the patients with supratentorial tumor lived longer than the patients with infratentorial tumor (p<0.05). Longer survival (survival length, years) was statistically less frequent in the patients in the EGFR FISH-positive group (p = 0.031). (C) 2010 Elsevier B.V. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | ELSEVIER SCIENCE BV | ko_KR |
dc.subject | Glioblastoma | ko_KR |
dc.subject | Prognosis | ko_KR |
dc.subject | Epidermal growth factor | ko_KR |
dc.subject | Brain neoplasm | ko_KR |
dc.subject | Tumor suppressor protein p53 | ko_KR |
dc.title | The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김봄이 | - |
dc.contributor.AlternativeAuthor | 명재경 | - |
dc.contributor.AlternativeAuthor | 박철기 | - |
dc.contributor.AlternativeAuthor | 백선하 | - |
dc.contributor.AlternativeAuthor | 김동규 | - |
dc.contributor.AlternativeAuthor | 정희원 | - |
dc.contributor.AlternativeAuthor | 박성혜 | - |
dc.identifier.doi | 10.1016/j.jns.2010.03.019 | - |
dc.citation.journaltitle | JOURNAL OF THE NEUROLOGICAL SCIENCES | - |
dc.description.citedreference | Puszynski K, 2008, J THEOR BIOL, V254, P452, DOI 10.1016/j.jtbi.2008.05.039 | - |
dc.description.citedreference | Buckley AF, 2008, AM J CLIN PATHOL, V129, P245, DOI 10.1309/WF10QAAED3PP93BH | - |
dc.description.citedreference | Gil-Benso R, 2007, CLIN NEUROPATHOL, V26, P224 | - |
dc.description.citedreference | Buckley AF, 2007, APPL IMMUNOHISTO M M, V15, P305 | - |
dc.description.citedreference | Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011 | - |
dc.description.citedreference | LOUIS DN, 2007, WHO CLASSIFICATION T | - |
dc.description.citedreference | Jeon YK, 2006, LUNG CANCER, V54, P387, DOI 10.1016/j.lungcan.2006.08.015 | - |
dc.description.citedreference | Puputti M, 2006, MOL CANCER RES, V4, P927, DOI 10.1158/1541-7786.MCR-06-0085 | - |
dc.description.citedreference | Nagpal J, 2006, ANTICANCER RES, V26, P4633 | - |
dc.description.citedreference | Kleinschmidt-DeMasters BK, 2006, BRAIN PATHOL, V16, P273 | - |
dc.description.citedreference | Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012 | - |
dc.description.citedreference | Xie D, 2005, ACTA NEUROPATHOL, V110, P481, DOI 10.1007/s00401-005-1072-y | - |
dc.description.citedreference | Joensuu H, 2005, J PATHOL, V207, P224, DOI 10.1002/path.1823 | - |
dc.description.citedreference | Dei Tos AP, 2005, EUR J CANCER, V41, P1383, DOI 10.1016/j.ejca.2005.03.018 | - |
dc.description.citedreference | Cappuzzo F, 2005, J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112 | - |
dc.description.citedreference | Hegi ME, 2005, NEW ENGL J MED, V352, P997 | - |
dc.description.citedreference | Ganigi PM, 2005, PEDIATR NEUROSURG, V41, P292, DOI 10.1159/000088731 | - |
dc.description.citedreference | Marquez A, 2004, DIAGN MOL PATHOL, V13, P1 | - |
dc.description.citedreference | KUMAR V, 2004, ROBBINS COTRAN PATHO | - |
dc.description.citedreference | Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069 | - |
dc.description.citedreference | Okada Y, 2003, CANCER RES, V63, P413 | - |
dc.description.citedreference | Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462 | - |
dc.description.citedreference | Steidl C, 2002, J PATHOL, V198, P115, DOI 10.1002/path.1175 | - |
dc.description.citedreference | Smith JS, 2001, J NATL CANCER I, V93, P1246 | - |
dc.description.citedreference | Lacroix M, 2001, J NEUROSURG, V95, P190 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.